Evaluation of CCR2 in Patients Post Myocardial Infarction

Phase 1 Unknown 90 enrolled Washington University School of Medicine

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

To determine the feasibility of 64Cu-DOTA-ECL1i, an investigational PET imaging drug, at the cellular level in the myocardium for individuals who have suffered a heart attack or who have other inflammatory heart disease.

Timeline

Start: 2018-11-24
Primary completion: 2025-11-24
Completion: 2025-11-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	64Cu-DOTA-ECL1i	Peptide	—	Other

Evaluation of CCR2 in Patients Post Myocardial Infarction

Summary

Timeline

Drugs

Indications